Association between low bone mass and the serum RANKL and OPG in patients with nephrolithiasis
BMC Nephrology Jul 17, 2018
Mansour A, et al. - The association between serum osteoprotegerin (OPG), receptor activator of nuclear factor kappaB ligand (RANKL) concentration, and bone mineral density (BMD) in patients with kidney stone disease was assessed in this analysis. Participants in the study were 44 nephrolithiasis patients with either low bone mass or normal BMD. By dual-energy X-ray absorptiometry (DEXA), BMD was measured at lumbar spine (L1-L4) and femoral neck. Using the ELISA method, the serum OPG and RANKL were determined. In patients with nephrolithiasis, high serum fasting OPG levels might be indicative of femoral neck BMD. However, no significant association was found between RANKL and bone densities.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries